Search
forResearch
5 / 71 resultsresearch Der Einfluss von pdHGF auf die Wundheilung
pdHGF speeds up wound healing and hair growth.
research Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane
Trilostane effectively and safely treats dogs with pituitary-dependent hyperadrenocorticism, improving symptoms and adrenal gland size.
research Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment
A diabetic cat with another gland issue got better after treatment with cabergoline, no longer needing insulin.
research Induction of autophagy improves skin and hair conditions in dogs with underlying diseases
Activating autophagy in dogs with certain diseases improves their skin and hair.
research Clinical and Imagistic Aspects in Dog’s Hyperadrenocorticism Determined by Pituitary and Adrenal Nodules with Secretory Function
Most dogs with Cushing's syndrome have pituitary tumors causing varied symptoms, complicating diagnosis.
Community Join
5 / 1000+ resultscommunity 6 month post-transplant, Dr Carman MD surgeon
A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.
community Has anybody here actually tried PTD-DBM?
community How much do we know about PTD-DBM?
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.